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Aims Measurement of change in carotid intima-media thickness (CIMT) has been proposed as an alterna-
tive for the occurrence of cardiovascular (CV) events in the assessment of therapeutic interventions.
Nevertheless, criticism has been voiced based on observations indicating a weak relation between
CIMT and coronary atherosclerosis as well as on the virtual absence of data showing that progression
of CIMT indeed predicts coronary artery disease (CAD) and stroke.
Methods and resultsWe set out to review the evidence on these issues by performing a literature search
on these topics. Of the 34 studies on the relation of CIMTwith coronary atherosclerosis, as assessed by
angiography (n ¼ 33) or intravascular ultrasound (n ¼ 1), 30 showed a modest positive relationship; the
magnitude of which was similar to that found in autopsy studies. Of all studies on CIMT and future CV
events (n ¼ 18), 17 showed graded positive relationships. At present, only one study has provided evi-
dence on the relation of change in CIMT and future CV events, showing an increased risk with CIMT pro-
gression. The paucity of data on progression and future CV risk is partly attributable to time windows
required to complete these studies.
Conclusion The modest relation between CIMT and coronary atherosclerosis most likely reﬂects varia-
bility in atherosclerosis development between the vascular beds rather than limitations of CIMT
measurements. Additional data on the relation between change in CIMTand future CV events is required
and currently is in progress.
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Introduction
Carotid intima-media thickness (CIMT) measurements have
increasingly been used in observational and intervention
studies. CIMT has been applied as an outcome variable in
studies on the determinants of atherosclerosis, and it has
been employed as an exposure variable in studies on the
prognostic value of CIMT in order to predict coronary
artery disease (CAD) and stroke. Change in CIMT over time
as a marker for atherosclerosis progression and possibly
change in cardiovascular risk, has predominantly served in
intervention studies as a primary outcome variable aimed
at assessing the effects of risk factor interventions. More
recently, reports on the determinants of progression of
CIMT have become available from observational studies.
The current widespread application of CIMT measurements
has been based on the validity, standardization, and
reproducibility of the measurement, and the evidence that
an increased CIMT can be regarded as a marker of athero-
sclerosis and of increased cardiovascular risk.1–7
Yet, criticism towards the value of these measurements
can also be heard throughout the scientiﬁc community.
Part of that comes from the observation that CIMT is a com-
bined measure of the intimal and medial layer of the arterial
wall, whereas the atherosclerotic process is restricted in
particular in its early phase, to the intimal layer only. Fur-
thermore, several reports point to the weak correlation
between increased CIMT and coronary atherosclerosis and
since the majority of the populations of the westernized
societies die from CAD, these ﬁndings can be regarded as
of great signiﬁcance. Finally, the virtual absence of data
showing that progression of CIMT predicts CAD and stroke
further supports criticism of the research utility of CIMT
measurements.
The current article attempts to provide an unbiased view,
based on a literature search, towards these latter two
aspects of criticism.
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Methods
Three literature searches were performed in the PubMed Medline
(www.ncbi.nlm.nih.gov) database. The ﬁrst search dealt with the
relation of CIMT with coronary atherosclerosis using statements
‘carotid intima-media thickness and coronary angiography; carotid
intimal medial thickness and coronary angiography; carotid intima-
media thickness and coronary atherosclerosis; carotid intimal
medial thickness and coronary atherosclerosis; carotid atherosclero-
sis and coronary atherosclerosis’. This yielded 329 hits. The second
search dealt with the relation of CIMT to risk of future events using
statements ‘carotid intima-media thickness and prediction; carotid
intimal medial thickness and prediction; carotid intima-media thick-
ness and cardiovascular events; carotid intimal medial thickness and
cardiovascular events’. This gave 58 hits. The third search dealt
with CIMT progression using statements ‘carotid intima-media thick-
ness progression; carotid intimal medial thickness progression’. This
gave 284 hits.
All abstracts were reviewed for appropriateness on the research
issue by one of the authors (M.L.B.), and if so, the article was
retrieved. Articles were considered appropriate if the quantitative
information in the abstract on the relation between CIMT and a
measure of coronary atherosclerosis, being based on a coronary
angiogram, coronary calcium, or intravascular ultrasound. Further-
more, information should be available on the population studied.
No restrictions were made to the manner by which the relation
was quantiﬁed. In addition, the references of the articles were
checked and the PubMed link ‘related articles’ was used to identify
additional papers. From search 1, 33 articles were found in the main
search, and one was identiﬁed through reference listing. For search 2,
these numbers were 12 and 6, respectively. For search 3, these
numberswere 1 and 0, respectively. All hits and articleswere reviewed
by one author only and this in theory might have biased the ﬁndings
when, for example, for search 1 those papers with strong relations
were selectively excluded. Yet, the inclusion criteria were wide, i.e.
if quantitative information on the relationship was provided, the
article was included. In addition, there is no direct beneﬁt for the
authors by doing so.
Results
CIMT and coronary atherosclerosis
Atherosclerosis is a systemic disease process and large sec-
tions of the arterial tree will suffer from atherosclerosis
when exposed to elevated risk factor levels. However, it is
well known that some parts, like the brachial artery, are
almost always spared from atherosclerotic involvement,
although studies show a positive correlation between CIMT
and brachial IMT.8 Also, the extent of atherosclerosis
differs across vessels like the femoral arteries, the abdomi-
nal aorta, the coronary arteries, and the carotid arteries.
This has been elegantly shown in a post-mortem study by
Pasterkamp et al.,9 who reported a ﬁve-fold difference in
extent of atherosclerosis between the common carotid
arteries and the coronary arteries, a three-fold difference
between common carotid arteries and the femoral arteries,
and a 1.5-fold difference between the coronary and femoral
arteries.
To appreciate the comparisons between measurements of
atherosclerosis obtained from various arterial beds, e.g.
carotid arteries vs. coronary arteries, a search for a gold
standard should be performed ﬁrst. In this particular case
the gold standard most likely constitutes post-mortem
studies. These are however scarce. In a post-mortem study
on 24 subjects, common CIMT measured by histopathology,
was compared with atherosclerosis of the femoral artery.
The correlation between mean distal common CIMTand rela-
tive plaque area in the femoral artery was 0.26, not statisti-
cally signiﬁcant, yet this sample size was exceedingly small.
Unfortunately, information on the comparison with coronary
atherosclerosis was not provided.10 These ﬁndings do agree
with data from autopsy studies performed around
1960,11–14 that also showed great variability and modest cor-
relations between carotid and coronary arterial beds of
around 0.3–0.5. Thus, if the autopsy studies are assumed
to have no measurement error, the upper limit of what
imaging studies may ﬁnd in terms of correlation is 0.50.
These results are indicative of the magnitude of correlations
that are to be expected when comparing atherosclerosis
measurements from two arterial beds.
Table 1 gives a summary of the ﬁndings reported in the
studies relating CIMT to coronary atherosclerosis.15–45 As is
clear from the table, CIMT has been measured in several
ways. CIMT can be measured in the common carotid artery
(CCA), the carotid bifurcation (BIF), and the internal
carotid artery (ICA). In addition to the three segments,
CIMT can be measured at the near wall of the arterial
segment (i.e. the ultrasound interface on the image
closest to the transducer) or at the far wall of the arterial
segment. Next to this, results of a measurement can be
expressed as a mean thickness over a length (usually
10 mm in the CCA) or as a maximum thickness of that
speciﬁc wall and segment. Finally, only one measurement
may be used in the analyses (e.g. mean far wall CCA), or
the segment and wall-speciﬁc measurements may be com-
bined into one CIMT estimate (e.g. mean max CIMT, i.e.
mean of all separate maximum measurements). At
present, there is however, no consensus of which CIMT
approach constitutes the ‘best’ CIMT measurement for
atherosclerosis assessment, for vascular risk assessment, or
for change over time in CIMT assessment.46 From Table 1 it
can be seen that in general, most of the studies (29 out of
33) showed a graded positive relationship, with correlation
coefﬁcients in the order of 0.3–0.4, although some report
lower or higher correlation coefﬁcients and some studies
showed no relationship at all (Table 1). In addition,
a study among 45 patients who underwent intravascular
ultrasound and carotid B-mode ultrasound reported that
the average maximum CIMT was signiﬁcantly related with
left main (LM) coronary atherosclerosis, as measured by
both mean and maximal plaque areas. The correlation coef-
ﬁcients were 0.39 and 0.41, respectively.47
From Table 1, it can been seen that the sample size does
not appear to impact the magnitude of the results. Both
large and small studies show a range of correlation coefﬁ-
cients. Also, from the four studies in which no relation
between CIMT and coronary atherosclerosis was reported,
two were small and two were large. Publication bias there-
fore does not appear to be a major issue.
CIMT and future vascular events
In Table 2, a summary is given of the available studies on the
role of CIMT in predicting future vascular events.48–66 In
general, studies among the general population showed a
gradual graded increase in risk with increased CIMT.
Studies carried out among populations with symptoms of
cardiovascular disease showed positive relations, albeit
the magnitude of the association differed across studies
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Table 1 Characteristics of the studies into the relation of CIMT and coronary atherosclerosis assessed by imaging techniques in cross-sectional studies
Publication
year
First author Data No. of
patients
Type of patients Type of
CIMT
Coronary
atherosclerosis
Findings Conclusion
(related
yes/no)Mean difference in
CIMT (mm)
OR Correlation
2005 Rohani8 FP 37 CAD CCA CAG; 50% 0,1,2,3,VD 0.44 þ
2004 Tagawa15 FP 26/12 CAD CCA þ
Hallerstam16 FP 111 CAD CCA MFR 0.23 þ
Wagenknecht17 FP 438 Family with type II
diabetics
CCA CAC 0.36 þ
Kablak18 FP 558 Suspect CAD CCA/BIF/
ICA
CAG; 50% 0,1,2,3,VD Graded þ
Paskierki103 FP 410 CCA CAG; 50% 0.66 vs. 0.64 2
Yildiz19 FP 79 Haemodialysis Plaque CAC 0.40 þ
Sonoda20 FP 23/21/15 CAD/HT/Con CCA MFR 0.51 þ
2003 Takiuchi21 FP 149 24 NT/125 HT CCA MFR 0.46 þ
Alan22 FP 180þ/532 CAD/control CCA CAG 2
Holaj23 FP 170 CAD CCA CAG þ
Sakaguchi24 FP 270 CAD CCA/BIF/
ICA
CAG 50% 0.84 vs. 1.08 2.71/sd þ
Orem104 FP 86 CAD CCA CAG abnormal/normal 0.89 vs. 0.76 þ
2002 Ishizu25 FP 90 CAD Mean max 75% 1.47 vs. 2.42 1.22/sd þ
Newman26 FP 414 General population ICA/CCA Calciﬁcations 1.63/sd
ICA
0.30 ICA þ
2.89/sd
CCA
0.12 CCA
Oei27 FP 2013 General population CCA Calciﬁcations 0.17 þ
Furumoto28 FP 45 Suspect CAD CCA ,50%; 50–90%; 90% 0.77/0.80/1.08 0.32 2
Belhasen29 FP 152 Valve surgery CCA CAG; 70% 0.58 vs. 0.70 0.45
Claessens30 FP 366 CABG/PTCA CCA CAG; 90% 0,1,2,3,VD Graded þ
2001 Teragawa31 FP 81 Suspect CAD CCA CAG; 50% 0.79 vs. 1.09 5.2 (ns) þ
Vasankari32 FP 62 Established CAD CCA CAG; 50% 0,1,2,3,VD Graded þ
Kato33 FP 104 Angina CCA 50% 0.84 vs. 0.99 5.85 þ
2000 Papamichael34 FP 165 CAD CCA/FEM CAG; 50% (Carotid)2
0,1,2,3,VD (Femoral)þ
Mack35 FP 133 CABG CCA CAG (lumen) 20.04 2
Balbarini36 FP 151 CAD CCA/BIF/
ICA
CAG 0.43 þ
Lekakis37 FP 224 CAD CCA CAG 50% Gensini þ
1999 Davis38 FP 318 General population CCA/BIF/
ICA
CAC (yes/no) 0.77 vs. 0.82 þ
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owing to differences in units of measurement of CIMT. Data
from the SMART study indicated that these positive associ-
ations also hold for patients with symptomatic coronary
heart disease, for patients with cerebrovascular disease,
and for patients with peripheral vascular disease.66
In most of the studies on the relation of CIMT and future
events, the magnitude of the relations attenuated consider-
ably when vascular risk factors were accounted for in the
analyses. The relationships were thus partly mediated by
risk factors, which further supports the notion that CIMT is
a measurement in which long-term exposure to elevated
risk factors is reﬂected. This notion has recently been
detailed.67
Determinants of change over time in CIMT
Data on determinants of change over time in CIMT comes
from observational studies and from randomized controlled
trials. CIMT measurements performed in observational
studies initiated around 1990 were not a priori set up for
assessment of change over time. As a result, reproducibility
of the CIMT measurement is much lower than in trials (intra-
class correlation of repeated measurement of CIMT of 0.59–
0.75 in observational studies and .0.90 in trials), and
measurement error higher; thus the reported associations
likely underestimate the true relationships. One of the ear-
liest reports from Salonen and co-workers with data on 100
subjects, indicated that increasing age, LDL cholesterol,
pack-years of smoking showed the strongest relationships
with 2-year progression of CIMT.68 In contrast, blood
pressure levels and HDL cholesterol were not related to pro-
gression of CIMT in this sample. Zureik et al.69 reported on
the relations of pulse pressure and 4-year change in
common CIMT among 957 healthy 59–71-year-old French
men and women in the E´tude du Vieillissement Arte´riel
(EVA) study. The AtheroGene Study among 502 subjects
with suspected CAD indicated that age, male gender, and
current smoking were determinants of common CIMT pro-
gression over a period of 2.5 years.70 The Atherosclerosis
Risk in Communities study among 12 644 middle aged and
women, reported diabetes, current smoking, HDL choles-
terol (in white men), and pulse pressure to be positively
related to increased progression of CIMT from 1987 to
1998.71 In addition, increase in baseline from 1987 to 1998
in LDL cholesterol, triglycerides, and onset of hypertension
and diabetes were positively related to increased pro-
gression. In contrast, results from the Cardiovascular
Heath Study among 65-year-old men and women revealed
no relations between established risk factors and 3-year pro-
gression of CIMT.72 Data from the Rotterdam study among
3409 men and women aged 55 years or over, with second
measurement after 6.5 years, indicated that moderate to
severe progression of common CIMT was related to age,
body mass index, male gender, current smoking, systolic
blood pressure, and hypertension. Lipid levels, however,
were not related to increased progression of common
CIMT.73 Recent information from the Carotid Atherosclerosis
Progression Study among 3383 men and women, with a
second CIMT measurement after 3 years, showed that age,
male gender, hypertension, diabetes, and smoking related
to increased progression of internal CIMT, whereas no
relation was found for common CIMT.74
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Table 2 Summary of prospective studies examining the relationship between CIMT and vascular events
First author CIMT measurement Clinical events associated
with CIMT
FU
(years)
Type of patient and (n) Age at
entry
(years)
Male
(%)
Unit of CIMT
measurement
(mm)
Adjusted RR (95% CI)
Salonen48 CCA and BIF Fatal and non-fatal MI 0.08–2.5 General population (1288) 42–60 100 0.1 1.11 (1.06–1.16)
Chambless49 CCA, BIF, ICA MI and coronary death 5.2 General population (12 841) 45–64 43 0.19 CCA M: 1.32 (1.13–1.54)
F: 1.92 (1.66–2.22)
Chambless50 CCA, BIF, ICA Non-fatal and fatal stroke 7.2 General population (14 214) 45–64 45 0.18 CCA M: 1.52 (1.28–1.80)
F: 1.72 (1.49–1.99)
O’Leary51 CCA and ICA MI and stroke 6.2 65 years (4476) 73 39 0.2 CCA 1.35 (1.25–1.45)
Bots52 CCA MI and stroke 2.7 55 years (7983) 71 64 0.16 Stroke 1.41 (1.25–1.82)
MI 1.43 (1.16–1.78)
Kitamura61 CCA and ICA combined Stroke 4.5 General population without
previous MI or stroke (1289)
60–74 100 Lowest vs. highest
quartile
5.2 [1.8–14.6]
Rosvall62 CCA MI or cardiac death 7 General population without
previous MI or stroke (5163)
46–68 0.10 1.23 [1.14–1.33]
Rosvall63 CCA Stroke 7 General population without
previous MI or stroke (5163)
46–68 0.10 1.20 [1.08–1.33]
Murakami64 CCA All-cause and vascular
mortality
3.2 75 years (298) 75 0.30 CVD 2.35 [1.03–5.37]
Lorenz65 CCA, BIF, ICA MI and stroke 4.2 19–90 years (5052) 19–90 0.16 MI: CCA: 1.16 [1.05–1.27]
MI: ICA: 1.06 [0.96–1.17]
Stroke: CCA: 1.11 [0.97–1.28]
Stroke: ICA: 1.10 [0.96–1.26]
Both: CCA: 1.17 [1.08–1.26]
Both: ICA: 1.09 [1.01–1.18]
Hodis53 CCA Coronary death and non-fatal
MI
8.8 CABG patients (146) 54 100 0.13 1.4 (1.1–1.8)
Held54 CCA, BIF ICA Non-fatal MI and CV death 3.0 Angina pectoris (558) 60 67 1.02 vs. 0.81 1.28 (0.59–2.78)
Nishizawa55 Carotid artery,
location not given
CV mortality 2.5 ESRD (438) 60 60 1.0–2.0 vs. 1.0 3.17 (1.41–7.17)
Benedetto56 CCA CV death 2.5 ESRD (138) 60 59 0.1 1.24 (1.06–1.44)
Kato57 CCA CV mortality 5 ESRD (219) 58 66 0.1 1.41 (1.12–1.78)
Lacroix58 CCA Worsening or recurrence of
cardiac symptoms
0.9 PTCA patients (123) 62 22 0.7 vs. 0.7 No independent predictor
Folsom59 CCA, BIF, ICA MI, coronary revascularization,
and CHD death
10.2 DM (1500) 45–64 43 1 M: 2.3 (not given)
F: 4.7 (not given)
Yamasaki60 CCA, BIF, ICA Angina pectoris and MI 3.1 DM type II (287) 62 43 1 4.9 (1.7–14.1)
Dijk66 CCA Coronary ischaemic events 2.8 CHD, stroke, and PAD patients 60 75 0.32 1.16 (1.01–1.34)
ESRD, end-stage renal disease; CHD, coronary heart disease; PAD, peripheral arterial disease; DM, diabetes mellitus; M, males; F, females; follow-up and age at entry are given as mean, median, or range.
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Where observational studies usually have only two CIMT
measurements over time and were not performed with an
a priori objective to measure change over time in CIMT,
such measurements in intervention studies are usually
done more often (annual, or every 6 months) and therefore
progression estimates are based on slope estimation from
several points rather than from points at baseline and end
of study only. Trials investigating the effect of blood
pressure lowering treatment on CIMT progression have
indeed shown that blood pressure lowering results in
reduced progression.75 In addition, results from randomized
controlled trials have consistently shown that lipid-lowering
reduces progression of CIMT or sometimes induces
regression.76–93
Change over time in CIMT and risk of future
events
Although many randomized controlled trials have been used
(change in CIMT) as primary outcome, and thus provide
excellent estimates of progression of CIMT over time, the
participants of these trials are usually not followed for the
occurrence of events after the trial has ﬁnished and thus
data on change in CIMT and future risk is very limited. To
the best of our knowledge, only one study has provided
information on the relation of change in CIMT and the risk
of future events. In a population of 146 men with coronary
artery disease, aged 40–59 years with a follow-up of 8.8
years, Hodis et al.94 showed that a 0.03 mm/year increase
in common CIMT was related to a 2.2-fold increased risk of
coronary events.
Another of the reasons for the paucity of this type of data
is the time window required to perform baseline and
follow-up measurements, and subsequently have cardiovas-
cular events to occur. To illustrate this point, manuscripts on
the relation of baseline CIMTand future CV events from large
observational studies took between 5 and 12 years to be
published. Given that recent papers from such studies on
determinants of progression have just been published, it is
obvious that it may take some time before a sufﬁcient
number of events have been collected to allow estimation
of relationships with sufﬁcient precision. However, such
data is urgently needed. Apart from the existing cohorts
that will provide evidence on this issue, the IMPROVE
study among 3600 subjects at high risk of vascular disease
recruited from seven European countries has been initiated
speciﬁcally to study determinants of progression of CIMT.95
Baseline data will be collected and after 15 months a
second CIMT measurement will be taken. Event follow-up
will continue up to 3 years. Results on progression are
expected at the end of 2007.
Discussion
In the present article, we have tried to address the limit-
ations in the assessment of (change in) CIMT as a suitable
alternative for CV events in studies on the effects of vascular
risk factors. Part of the criticism has come from observations
indicating a weak relation between CIMT and coronary
atherosclerosis. In fact the majority of the published
reports revealed relationships between coronary athero-
sclerosis and CIMT in the expected direction. Furthermore,
the associations are of a similar magnitude to that shown
in autopsy studies. Thus, a modest relation between CIMT
and coronary atherosclerosis most likely reﬂects variability
in atherosclerosis development between the vascular beds
rather than limitations in CIMT measurements.
A second limitation dealt with the virtual absence of data
showing that progression of CIMT predicts coronary heart
disease and stroke. The limited data on this issue may to
some extent be attributable to the time windows required
for these studies in their generation of results. Moreover,
since the earlier observational studies using CIMT measure-
ment have more measurement error when compared with
more recent studies, they need larger sample sizes and a
larger number of events to provide precise and stable esti-
mates of CIMT progression. Therefore, this lack of infor-
mation remains to be addressed.
A third critique deals with the observation that CIMT is a
combined measure of the intimal and medial layer of the
vessel wall, and that the atherosclerotic process is
restricted in particular in its early phase to the intimal
layer only. Indeed, studies comparing far wall B-mode ultra-
sound with histology showed that the combined intima and
media is measured.96–99 Nevertheless, the relations
between measured CIMT and measured coronary athero-
sclerosis appear to be of the same magnitude as those
seen in autopsy studies.
For a measurement to be suitable as an alternative for CV
events in intervention studies, criteria have been proposed
(Table 3).46,100 Recently, Espeland et al.101 applied these
two sets of criteria to evaluate whether change in CIMT
might be suitable as an alternative for CV events in seven
lipid-lowering trials. In the article, Espeland showed that
lipid-lowering therapy already affects progression of CIMT
before a reduction in events can be established, using a
smaller number of subjects and a shorter time frame when
compared with an event trial. Furthermore, evidence was
Table 3 Criteria for surrogacy proposed by Boissel101 and
Prentice46
Clinical criteria for surrogacy (Boissel)
B1: Efﬁciency
Relatively easy to measure, preferably non-invasively
Trials should be smaller and of shorter duration
Changes in surrogate should precede clinical endpoints so
that progression may be assessed more quickly
B2: Linkage
Quantitative and qualitative relation between surrogate and
event
B3: Congruency
Surrogate should produce parallel estimates of risk and
beneﬁt.
Changes in events should be deductible from observed
changes in surrogate
Statistical criteria for surrogacy (Prentice)
P1: The intervention should affect the distribution of the
endpoint
P2: The intervention should affect the distribution of the
surrogate
P3: The distribution of the endpoint should dependent on
surrogate
P4: The surrogate should fully account for the impact of the
intervention on the endpoint
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provided that change in CIMT progression due to
lipid-lowering therapy, in part, explained the reduction in
vascular events.101 A similar analysis for blood pressure-
lowering treatment was recently reported by Wang et al.102
In conclusion, at present, multiple lines of evidence are
supportive of assessment of change in CIMTas an alternative
for cardiovascular events to study effects of interventions.
A modest relation between CIMT and coronary atherosclero-
sis most likely reﬂects variability in atherosclerosis develop-
ment between the vascular beds rather than a poor CIMT
measurement. Additional data on the relation between
change in CIMT and future CV events is urgently required
and currently is in progress.
Conﬂict of interest: none declared.
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